48results about "Endopeptidase" patented technology

This disclosure provides an alpha-1 antitrypsin (AAT) polypeptide as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, and methods of producing the AAT polypeptide and method of using the AAT polypeptide in therapy.

The invention discloses application of an alpha-amylase / subtilisin inhibitor LASI gene in improvement of drought resistance and salt resistance of crops. The nucleotide sequence of the Ligusticum wallichii LASI gene is as shown in SEQ ID NO. 1; transgenic arabidopsis thaliana plants are obtained through genetic engineering and transgenic identification methods, the drought resistance and the salt resistance of transgenic and wild type arabidopsis thaliana are analyzed through growth indexes and biochemical indexes, and LASI transgenic arabidopsis thaliana with the drought resistance and the salt resistance is successfully obtained. The invention provides a new gene source for cultivating crops with stronger drought resistance and salt tolerance by utilizing a gene engineering technology.

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Use of a fructose disaccharide or fructooligosaccharide, for increasing protein production in Bifidobacterium longum subsp longum.

Among other things, polypeptides are disclosed that inhibit or suppress the activity of kallikrein-related proteases and are therefore useful for treating diseases and conditions associated with dysregulated kallikrein-related protease activity. Pharmaceutical compositions and methods of treatment using the polypeptides and pharmaceutical compositions are also provided.

The invention relates to methods of assessing liver disease in a subject by detecting one or more single-nucleotide polymorphisms (SNPs) of the subject and correlating the detected SNPs to the liver disease. The methods may also include a step of implementing a treatment decision, such as monitoring the subject for signs of liver disease, administering a therapeutic agent to the subject, liver transplant, or combinations thereof. The invention also relates to computing devices for assessing liver disease in a subject.

This disclosure provides alpha-1 antitrypsin (AAT) polypeptides as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, methods for producing the AAT polypeptide, and methods for using the AAT polypeptide in therapy.

The invention discloses a preparation method and application of a PSA-ACT compound recombinant protein. The preparation method comprises the following steps: obtaining gene segments of recombinant PSA and ACT proteins; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation, transfection, induction and fermentation broth separation and purification operation on the recombinant plasmid to obtain recombinant PSA and ACT proteins; then activating PSA recombinant protein by using metalloproteinase, and then mixing ACT with the activated PSA to obtain a mixture containing the PSA, ACT and a PSA-ACT compound; and finally, purifying by using an ion exchange chromatography technology and a hydrophobic chromatography technology in sequence to obtain the high-purity and high-activity PSA-ACT compound. According to the method, the spontaneous reaction of ACT and activated PSA is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, and the recombinant protein can be produced on a large scale; the PSA-ACT recombinant protein prepared by the method disclosed by the invention has very strong immunoreactivity.

The present invention relates to extracts of bacteria of the genus Sphingomonas, compositions comprising at least one bacterium of the genus Sphingomonas or said extracts, their uses, and their implementation in cosmetic methods.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

Wound healing is a process by which these wounds on the skin of a subject heal and eventually close. When the injured surface is large, becomes infected, or in patients with poor healing capacity such as diabetics or the elderly or bedridden patients, then wound healing can be prolonged and lead to chronic ulceration and further complications with even limb loss or increased morbidity and mortality. This invention is directed to a topical formulation for promoting wound healing, and wound dressings and bandages comprising the same.

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The application relates to the field of agricultural biotechnology, in particular to an LMSerpinb1 gene and application thereof. A locusta migratoria serpinb1 gene is cloned, and the locusta migratoria mortality and the gene expression amount change of the target gene in the locusta migratoria are detected through the method of mixed feeding of the locusta migratoria with metarhizium anisopliae, so that the role of the locusta migratoria in the metarhizium anisopliae infection is verified, and a foundation for further clarifying the action mechanism of Serpin is laid.

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

A peptide library comprising a plurality of different peptides. The peptides each comprise an amino acid sequence encoded by a nucleotide sequence consisting of the sequence of SEQ ID NO: 14. The nucleotide sequence has been modified by replacing a nucleotide sequence consisting of the 43rd base thymine to the 93rd base thymine with a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1. The peptide library has a diversity of at least 1 × 105. In SEQ ID NO: 1, each of the 1st Xaa to the 5th Xaa, the 7th Xaa, the 9th Xaa, and the 10th Xaa in each peptide is independently any amino acid other than cysteine and proline. Each of the 6th Xaa and the 8th Xaa in each peptide is independently any amino acid other than cysteine. The 11th Xaa in each peptide is independently selected from tyrosine, serine, phenylalanine, leucine, and threonine. The 12th Xaa in each peptide is independently selected from asparagine, aspartic acid, leucine, lysine, glutamine, alanine, and glutamic acid.

The present invention provides methods and compositions for reducing internalization and / or trafficking of tau in neuronal cells comprising contacting the cells with an effective amount of an LRP1 and / or SorLA antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of an LRP1 and / or SorLA antagonist.

Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen.

To provide a target binding peptide.SOLUTION: A target-binding peptide obtained by a method comprising the steps of: bringing a peptide contained in a peptide library into contact with a target molecule; recovering a peptide bound to the target molecule; and preparing the recovered peptide by gene recombination.SELECTED DRAWING: None

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

The present invention relates to protein prodrug constructs, e.g., protein fusion constructs, comprising complement 3 and pregnancy zone protein-like alpha-2-macroglobulin domain (CPAMD)-containing proteins (e.g., A2M) and one or more drugs, and acting as protease activatable prodrugs. The invention also relates to the release mechanism of the CPAMD protein and the development of multispecific drugs, such as bispecific drugs.

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

This invention belongs to the fields of molecular biology, genetic engineering, and protein engineering; specifically, it relates to a Pacifastin serine protease inhibitor PqPI expressed in the venom of the grassland caterpillar wasp, its encoded nucleic acid sequence, and functional studies. This invention provides a Pacifastin serine protease inhibitor PqPI from the grassland caterpillar wasp, which has the amino acid sequence shown in SEQ ID NO:2. This invention also provides the use of the above-mentioned Pacifastin serine protease inhibitor PqPI from the grassland caterpillar wasp: for the preparation of Pacifastin serine protease inhibitors from the grassland caterpillar wasp, which can be used to inhibit the activation of PPO in the hemolymph of grassland caterpillars or cabbage caterpillars.

A method, system, and composition related to the preparation of samples for glycoproteomic analysis is described. The sample preparation process can include a proteolytic digestion step followed by a measurement step of the glycopeptide and peptide amounts in the proteolytic digest using a liquid chromatography-mass spectrometry system. Optionally, the sample preparation process can also include the collection of the sample on an absorbent or bibulous member where the proteins and glycoproteins are later extracted and then digested for glycoproteomic analysis. Glycopeptide and peptide measurements of biological samples were analyzed to provide a diagnosis of a disease such as, for example, ovarian cancer or to assess whether a patient with melanoma is likely or not likely to benefit from checkpoint inhibitor therapy.

The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and / or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

The invention relates to the technical field of biology, in particular to a PEDF mutant targeting VEGFR2 (vascular endothelial growth factor receptor 2) and application of the PEDF mutant in fundus neovascularization diseases. The sequence of the PEDF mutant of the targeted VEGFR2 is as shown in SEQ ID NO: 1. The invention provides a single injection recombinant adeno-associated virus (rAAV) gene therapy, which is used for treating VEGF (vascular endothelial growth factor) related eye diseases. The therapy prevents neovascularization by inducing expression of a mutant pigment epithelium-derived factor (PEDF). The method comprises the following steps: firstly, establishing two animal models of fundus neovascularization diseases, namely an extremely low density lipoprotein receptor gene knockout (Vldlr <- / ->) mouse model and an oxygen-induced ischemic retinopathy (OIR) mouse model; subsequently, anti-angiogenesis factors are injected into a vitreous cavity, and the result shows that clinically remarkable vasculopathy is almost completely inhibited in the established mouse fundus neovascularization model.